疑难病杂志
疑難病雜誌
의난병잡지
JOURNAL OF DIFFICULT AND COMPLICATED CASES
2014年
1期
30-33
,共4页
许德志%王勇%徐军%朱玉方%陶荣杰
許德誌%王勇%徐軍%硃玉方%陶榮傑
허덕지%왕용%서군%주옥방%도영걸
Ommaya囊%放射疗法%化学疗法%脑转移瘤,囊性
Ommaya囊%放射療法%化學療法%腦轉移瘤,囊性
Ommaya낭%방사요법%화학요법%뇌전이류,낭성
Ommaya sac%Radiotherapy%Chemotherapy%Metastatic brain tumors,cystic
目的:观察放化疗联合Ommaya囊置入治疗囊性脑转移瘤的有效性及安全性。方法40例囊性脑转移瘤患者随机分为2组:Ommaya组24例,对照组16例。 Ommaya组行Ommaya囊置入术,同时进行同步放化疗及瘤内化疗;对照组仅进行同步放化疗,均4周为1个疗程。2组均随访至2013年6月,比较2组的近期疗效、中位生存时间( MOS)、生存率及治疗相关不良反应。结果 Oommaya 组治疗后客观有效率为91敂.7%,高于对照组62.5%( P <0.05)。 Oommaya组的中位生存期为16月,对照组的中位生存期为6月。 Ommaya组6个月、1年、2年生存率分别为83.3%、75.0%和25.0%,明显高于对照组的50.0%、18.8%和0( P <0.05)。患者的耐受性好,2组相关不良反应比较差异无统计学意义( P <0.05)。结论放化疗联合Ommaya囊内化疗治疗囊性脑转移瘤,其疗效优于单纯放化疗,且不良反应轻,患者耐受性好。
目的:觀察放化療聯閤Ommaya囊置入治療囊性腦轉移瘤的有效性及安全性。方法40例囊性腦轉移瘤患者隨機分為2組:Ommaya組24例,對照組16例。 Ommaya組行Ommaya囊置入術,同時進行同步放化療及瘤內化療;對照組僅進行同步放化療,均4週為1箇療程。2組均隨訪至2013年6月,比較2組的近期療效、中位生存時間( MOS)、生存率及治療相關不良反應。結果 Oommaya 組治療後客觀有效率為91敂.7%,高于對照組62.5%( P <0.05)。 Oommaya組的中位生存期為16月,對照組的中位生存期為6月。 Ommaya組6箇月、1年、2年生存率分彆為83.3%、75.0%和25.0%,明顯高于對照組的50.0%、18.8%和0( P <0.05)。患者的耐受性好,2組相關不良反應比較差異無統計學意義( P <0.05)。結論放化療聯閤Ommaya囊內化療治療囊性腦轉移瘤,其療效優于單純放化療,且不良反應輕,患者耐受性好。
목적:관찰방화료연합Ommaya낭치입치료낭성뇌전이류적유효성급안전성。방법40례낭성뇌전이류환자수궤분위2조:Ommaya조24례,대조조16례。 Ommaya조행Ommaya낭치입술,동시진행동보방화료급류내화료;대조조부진행동보방화료,균4주위1개료정。2조균수방지2013년6월,비교2조적근기료효、중위생존시간( MOS)、생존솔급치료상관불량반응。결과 Oommaya 조치료후객관유효솔위91구.7%,고우대조조62.5%( P <0.05)。 Oommaya조적중위생존기위16월,대조조적중위생존기위6월。 Ommaya조6개월、1년、2년생존솔분별위83.3%、75.0%화25.0%,명현고우대조조적50.0%、18.8%화0( P <0.05)。환자적내수성호,2조상관불량반응비교차이무통계학의의( P <0.05)。결론방화료연합Ommaya낭내화료치료낭성뇌전이류,기료효우우단순방화료,차불량반응경,환자내수성호。
Objective To observe the efficacy and safety of chemoradiotherapy combined Ommaya sac placement for treatment of cystic brain metastases .Methods 40 cases of cystic brain metastases were randomly divided into two groups:Ommaya group of 24 patients , control group of 16 patients , Ommaya group underwent Ommaya capsule implantation , concur-rent chemoradiotherapy and intratumoral chemotherapy; control group for concurrent chemoradiotherapy are four weeks of a course of treatment .Two groups were followed up to June 2013 , compared two groups of short-term effect , the median survival time (MOS), survival, and treatment-related adverse reactions.Results The Ommaya group after treatment, objective re-sponse rate was 91.7%, higher than 62.5%of the control group ( P <0.05).Ommaya group, the median survival time was 16 months, in the control group, the median survival time was 6 months.Ommaya group at 6 months, 1-year, 2-year survival rates were 83.3%, 75.0%and 25.0%, significantly higher than 50.0%, 18.8%, and 0 ( P <0.05).Well tolerated by patients, two groups of related adverse reactions was no significant difference ( P <0.05).Conclusion Chemoradiotherapy combined Ommaya sac placement for treatment of cystic brain metastases , its efficacy is superior to chemotherapy alone , and the adverse reactions were mildly , patients tolerated well .